Highlights Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Delayed Nasdaq Other stock markets 12:33:53 2024-04-29 pm EDT			5-day change	1st Jan Change
2.85 ^USD	-8.06%		-13.64%	-10.97%

Mar. 26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	Feb. 07	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	23-10-31	CI
Virpax Forms New Unit Novvae Pharmaceuticals	23-09-18	MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	23-09-18	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method	23-08-10	CI
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate	23-07-13	MT
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	23-02-13	RE
Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology	23-02-13	CI
Virpax Pharmaceuticals Says it has Received Pre-IND Application Guidance From the US FDA on NobrXiol's Development	22-12-14	MT
Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)	22-12-14	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Virpax Pharmaceuticals Says to Pursue OTC Medical Device Regulatory Pathway for AnQlar to Prevent Influenza, COVID-19	22-07-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Highlights

Filters